目前关于西妥昔单抗治疗乳腺癌的研究较少。
But there are few studies on Cetuximab for treating Breast Cancer.
本文综述了西妥昔单抗的药理作用及临床评价。
The pharmacologic actions of cetuximab and its clinical evaluation are reviewed in this paper.
共完成了572周的西妥昔单抗治疗，中位周期数为8周。
A total of 572 weeks (median, 8 weeks) of cetuximab treatment were completed.
现在，西妥昔单抗毕竟还是获批了，英克隆的股价也已反弹。
Now, Erbitux has been approved after all, and ImClone's stock has rebounded.
法国及美国应用西妥昔单抗治疗直肠结肠癌最多，而芬兰最低。
The use of cetuximab for colorectal cancer was highest in France and the United States and lowest in Finland.
两项对联合应用贝伐单抗和西妥昔单抗的随机试验结果还须等待。
The results of two randomized trials looking at the combination of bevacizumab and cetuximab are awaited.
欧洲药品局emea已经限制西妥昔单抗和帕尼单抗在这些患者使用。
EMEA, the European Medicines Agency, has already restricted use of cetuximab and panitumumab to such patients.
目的：探讨西妥昔单抗联合化疗治疗转移性结直肠癌的疗效和不良反应。
Objective: to determine the therapeutic effect and toxicity of cetuximab and chemotherapy agents in metastatic colorectal cancer.
英克隆将提留西妥昔单抗在美收入的39%，而百时美施贵宝将获得其余部分。
ImClone will keep 39 per cent of US revenues from Erbitux, with Bristol-Myers Squibb taking the rest.
但这些称为EGFR抑制因子如西妥昔单抗的药物对结肠癌的治疗还不是很有效。
But these drugs called EGFR inhibitors, such as cetuximab, have not been very effective against colon cancer.
我们的研究显示单次剂量的西妥昔单抗可以明显影响肿瘤增殖和炎症基因的表达。
Our study showed that a single dose of cetuximab has a significant impact on the expression of genes involved in tumor proliferation and inflammation.
结论：我们的研究显示单次剂量的西妥昔单抗可以明显影响肿瘤增殖和炎症基因的表达。
Conclusion Our study showed that a single dose of cetuximab has a significant impact on the expression of genes involved in tumor proliferation and inflammation.
最新的研究看出如果加用西妥昔单抗(又名爱比妥)可以明显增加这种手术切除的优势。
The new study aimed to see if addition of the drug cetuximab, also known as Erbitux, would help patients even more.
由于ERBB2不受西妥昔单抗的影响，这是一种使癌症对药物产生耐药性的简单方法。
Because ERBB2 isn't affected by cetuximab, this is an easy way for cancers to become resistant to the drug.
本文旨在观察西妥昔单抗联合放疗对中国局部晚期头颈部鳞癌患者的近期疗效和安全性。
This paper aims to observe the short term efficiency and safety of Cetuximab combined with radiotherapy of head and neck squamous Cell carcinoma in Chinese patients.
治疗前先行活组织检查和血浆样本的采集，西妥昔单抗应用之前，CRT之前，即手术的时机。
Biopsies and plasma samples were taken before treatment, after cetuximab but before CRT, and at the time of surgery.
蛋白组学和微数列用来检测西妥昔单抗的分子有效性并且明确生物标记物对疗效的预测方面的作用。
Proteomics and microarrays were used to monitor the molecular response to cetuximab and to identify profiles and biomarkers to predict treatment efficacy.
目的作为EGFR抑制剂，西妥昔单抗在多种实体瘤中应用日益广泛，显示出良好的疗效和安全性。
Objective As EGFR inhibitor, Cetuximab has been widely used in several solid tumors, and has perfect therapeutic effect and security.
差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。
The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.
例如，委员会使用的关于单克隆抗体西妥昔单抗和帕尼单抗(它们抑制转移性结直肠癌的表皮生长因子受体egfr)的数据。
For example, the Panel used data for the monoclonal antibodies cetuximab and panitumumab, which inhibit the EGF receptor (EGFR) in metastatic colorectal cancer.
方法：我们随机分组表皮生长因子受体阳性、转移性、不可切除结直肠癌患者接受FOLFIRI单独化疗或联合西妥昔单抗化疗。
Methods We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.
结论：这些结果证实了：KRAS突变对于转移性CRC患者使用西妥昔单抗治疗时对西妥昔单抗耐药情况和生存期具有很高的预测价值。
Conclusion: These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetuximab.
特拉比斯教会的修羽士颠末变革的上帝教西妥修道会的次要一支的成员，以苦行和赌咒缄默为特性，1664年树立于法国东南部的拉特拉比斯修道院。
A member of the main, reformed branch of Cistercian monks, characterized by austerity and a vow of silence, established in1664 at La Trappe Monastery in northwest France.
西格蒙德·弗洛伊德(Sigmund Freud)沉迷于莎士比亚和陀思妥耶夫斯基，并以索福克勒斯（Sophocle 古希腊悲剧诗人）的悲剧角色命名了俄狄浦斯情节。
Sigmund Freud named the Oedipus complex for Sophocles' tragic character and was fascinated with Shakespeare and Dostoevsky.
根据交易条款，兰伯西也将能够出售的通用版本的立普妥在加拿大，比利时，荷兰，德国，瑞典，意大利和澳大利亚。
Under terms of the deal, Ranbaxy will also be able to sell generic versions of Lipitor in Canada, Belgium, the Netherlands, Germany, Sweden, Italy and Australia.
辉瑞和兰伯西已锁定在争端关于立普妥的专利自2003年以来。
Pfizer and Ranbaxy have been locked in dispute regarding Lipitor patents since 2003.
专利侵权诉讼之间的辉瑞和兰伯西超过立普妥将继续在芬兰，西班牙，葡萄牙，丹麦和罗马尼亚。
Patent infringement litigation between Pfizer and Ranbaxy over Lipitor will continue in Finland, Spain, Portugal, Denmark and Romania.
P 4 5 02c9的底物包括甲苯磺丁脲、苯妥英、s法华令、氟西汀、洛沙坦等。
P450 2c9 substrates mainly include tolbutamide, phenytoin, S-warfarin, fluoxetine, and losartan.
P 4 5 02c9的底物包括甲苯磺丁脲、苯妥英、s法华令、氟西汀、洛沙坦等。
P450 2c9 substrates mainly include tolbutamide, phenytoin, S-warfarin, fluoxetine, and losartan.
应用推荐